MedTech, Industrial Impact

Bispecific Antibodies - CMC Considerations

December 16, 2022

Bispecific Antibodies
Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

Spotlight

BioDuro

BioDuro is a global provider of contract research, development and manufacturing outsourcing solutions. Pharmaceutical, biotechnology and virtual companies are offered a comprehensive array of scientific services spanning the drug discovery and development continuum. Our precise balance of scientific rigor and flexibility enables fast, informed decision-making and maximizes the chances of success at every stage of any project.

OTHER WHITEPAPERS
news image

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

Read More
news image

Lentivirus production study in the scale-X™ fixed-bed bioreactor

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

Read More
news image

Quality Control Solutions for Cell and Gene Therapy

whitePaper | September 10, 2022

Droplet Digital PCR (ddPCR) provides highly precise and absolute quantification of nucleic acids by counting nucleic acid molecules encapsulated in discrete water-in-oil droplets.

Read More
news image

A Review of RNA Analysis using the Agilent AutomatedElectrophoresis Portfolio

whitePaper | July 15, 2022

Good-quality RNA is crucial to the success of many downstream applications, including qPCR, microarray analysis, and RNA sequencing. Agilent automated

Read More
news image

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Read More
news image

Multi-Attribute Methods for Biopharmaceutical Analysis

whitePaper | December 5, 2022

The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.

Read More

Spotlight

BioDuro

BioDuro is a global provider of contract research, development and manufacturing outsourcing solutions. Pharmaceutical, biotechnology and virtual companies are offered a comprehensive array of scientific services spanning the drug discovery and development continuum. Our precise balance of scientific rigor and flexibility enables fast, informed decision-making and maximizes the chances of success at every stage of any project.

Events